Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma
The purpose of this study is to test the safety and effectiveness of erlotinib and chemoradiotherapy in patients with unresectable esophageal or gastro-esophageal squamous cancer .
Esophageal Squamous Carcinoma
DRUG: Paclitaxel|DRUG: Erlotinib|RADIATION: Radiation therapy
Progression free survival, 2 year
Tumor response rate, 1 year|disease control rate, 1 year|overall survival, 5 year|adverse events, 5 year
The purpose of this study is to test the safety and effectiveness of erlotinib and chemoradiotherapy in patients with unresectable esophageal or gastro-esophageal squamous cancer .